JP2022545967A5 - - Google Patents
Info
- Publication number
- JP2022545967A5 JP2022545967A5 JP2022513859A JP2022513859A JP2022545967A5 JP 2022545967 A5 JP2022545967 A5 JP 2022545967A5 JP 2022513859 A JP2022513859 A JP 2022513859A JP 2022513859 A JP2022513859 A JP 2022513859A JP 2022545967 A5 JP2022545967 A5 JP 2022545967A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- pharmaceutical composition
- composition according
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891799P | 2019-08-26 | 2019-08-26 | |
| US62/891,799 | 2019-08-26 | ||
| US201962902352P | 2019-09-18 | 2019-09-18 | |
| US62/902,352 | 2019-09-18 | ||
| US202063004258P | 2020-04-02 | 2020-04-02 | |
| US63/004,258 | 2020-04-02 | ||
| PCT/US2020/047733 WO2021041373A1 (en) | 2019-08-26 | 2020-08-25 | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545967A JP2022545967A (ja) | 2022-11-01 |
| JP2022545967A5 true JP2022545967A5 (enExample) | 2023-09-01 |
Family
ID=72473961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513859A Pending JP2022545967A (ja) | 2019-08-26 | 2020-08-25 | 完全ヒト翻訳後修飾抗ＶＥＧＦ Ｆａｂを用いる糖尿病性網膜症の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220280608A1 (enExample) |
| EP (1) | EP4021936A1 (enExample) |
| JP (1) | JP2022545967A (enExample) |
| KR (1) | KR20220051246A (enExample) |
| CN (1) | CN114502197A (enExample) |
| AU (1) | AU2020336314A1 (enExample) |
| BR (1) | BR112022003811A2 (enExample) |
| CA (1) | CA3149401A1 (enExample) |
| IL (1) | IL290863A (enExample) |
| MX (1) | MX2022002366A (enExample) |
| TW (1) | TWI914315B (enExample) |
| WO (1) | WO2021041373A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024178225A1 (en) * | 2023-02-22 | 2024-08-29 | Cornell University | Gene therapy mediated angiogenesis to enhance survival of transplanted fat |
| WO2025081143A1 (en) * | 2023-10-14 | 2025-04-17 | City Labs, Inc. | Radioluminescent eye device for modulation of photoreceptor metabolism |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| IL134643A0 (en) | 1997-08-27 | 2001-04-30 | Ariad Gene Therapeutics Inc | Chimeric transcriptional activators and compositions and uses related thereto |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| WO2013177215A1 (en) | 2012-05-24 | 2013-11-28 | Altaviz Llc | Viscous fluid injector |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| EP3223760B1 (en) | 2014-11-28 | 2020-01-08 | Visionisti OY | Ocular therapeutics tool |
| USD878575S1 (en) | 2015-11-24 | 2020-03-17 | Visionisti Oy | Hand operated medical instrument |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
| US10912883B2 (en) | 2017-11-04 | 2021-02-09 | Altaviz, Llc | Gas-powered fluid injection system |
| CN111417423B (zh) | 2017-11-04 | 2022-10-11 | 奥特威资有限责任公司 | 注射装置及其制造和使用方法 |
| CN108103104B (zh) | 2017-12-21 | 2021-07-06 | 北京锦篮基因科技有限公司 | 一种预防和治疗脉络膜新生血管相关眼部疾病的基因药物 |
-
2020
- 2020-08-25 CA CA3149401A patent/CA3149401A1/en active Pending
- 2020-08-25 EP EP20771671.3A patent/EP4021936A1/en active Pending
- 2020-08-25 KR KR1020227009810A patent/KR20220051246A/ko not_active Ceased
- 2020-08-25 MX MX2022002366A patent/MX2022002366A/es unknown
- 2020-08-25 WO PCT/US2020/047733 patent/WO2021041373A1/en not_active Ceased
- 2020-08-25 US US17/638,517 patent/US20220280608A1/en active Pending
- 2020-08-25 TW TW109129003A patent/TWI914315B/zh active
- 2020-08-25 AU AU2020336314A patent/AU2020336314A1/en active Pending
- 2020-08-25 CN CN202080070135.9A patent/CN114502197A/zh active Pending
- 2020-08-25 JP JP2022513859A patent/JP2022545967A/ja active Pending
- 2020-08-25 BR BR112022003811A patent/BR112022003811A2/pt unknown
-
2022
- 2022-02-24 IL IL290863A patent/IL290863A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7111924B2 (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2025000642A5 (enExample) | ||
| JP2022153418A5 (enExample) | ||
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2021503914A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| JP2015523060A5 (enExample) | ||
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| CN110423281B (zh) | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 | |
| JP2022522776A5 (enExample) | ||
| WO2011079175A1 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| US20250170276A1 (en) | Gene delivery vector for delivering human vegf receptor fusion protein and use thereof | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| Shim et al. | Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration | |
| WO2025103416A1 (zh) | 用于老年相关性黄斑变性的治疗的基因治疗药物 | |
| JP7766054B2 (ja) | 眼病態の処置のためのｄｎａ構造 | |
| Wu et al. | Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy | |
| JP2025534347A (ja) | 抗ｖｅｇｆ ｆａｂをコードする組換えウイルスベクターを用いる眼疾患の処置 | |
| CN117089560A (zh) | 融合核酸、腺相关病毒载体及其用途和药物制剂 | |
| EP4703378A1 (en) | Drug for relieving ocular angiogenesis related diseases and use thereof | |
| CN118186005A (zh) | 一种适于阿达木单抗的表达盒及其载体与应用 | |
| HK40105223A (en) | An expression cassette suitable for adalimumab and its vector and application | |
| JP2024525186A (ja) | 網膜障害 | |
| AU2022270607A1 (en) | Compositions and methods related to the treatment of ocular diseases in equines | |
| CN117535299A (zh) | 分离的核酸分子、重组病毒或其应用 |